An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II.

ABSTRACT:

Introduction

Icatibant, a first-in-class B2 bradykinin receptor antagonist, appears to have a favorable efficacy and safety profile for the treatment of acute attacks of hereditary angioedema in adults.

Aims

To update the evidence and provide an overview of the available data on icatibant.

Evidence review

Peer reviewed articles published and listed in Medline Search and published updated guidelines for the treatment of acute attacks in hereditary angioedema type I and II in adults were reviewed. The validity and quality of evidence were evaluated.

Place in therapy

Clinical evidence for the treatment of acute hereditary angioedema attacks with icatibant is strong. Approximately 10% of the patients require a second dose. No serious adverse reactions have been rep

SUBMITTER: Floccard B 

PROVIDER: S-EPMC3467996 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature